Our NIH R01 has enabled us to develop new instrumentation for the X-ray footprinting experiment, making the method more automated and accessible to even more people. As of 2021, we also have an NIH R21 focused on using footprinting to characterize early stage oligomeric forms of the amyloid beta protein, which is highly relevant to the disease progression in Alzheimer's Disease.

R21 AG072478